Phytogen Life Sciences Inc.
Phytogen Life Sciences Inc. is in the business of developing,
manufacturing, and commercializing pharmaceuticals
derived from natural sources. Phytogen is a manufacturer
of pharmaceutical grade paclitaxel, a novel anti-tumour agent
referred to in some scientific and medical literature
as 'taxol.'
Paclitaxel has been shown to be a safe and effective agent in
the treatment of advanced ovarian and breast cancer, and in
other forms of the disease. The total market for paclitaxel
reached US $1.6 billion in 2000, and it use is expected to
continue to grow as new indications for the use of Taxol are
approved.
In 1994 the company completed construction of a 22,000
sq.ft. building equipped to produce paclitaxel as a bulk
pharmaceutical product to clinical purity standards under
cGMP. In 1996 Phytogen filed a Drug Master File with the
US Food and Drug Administration in preparation for
marketing in the United States. The Companys state-of-the-art
production facility in British Columbia is operated in
accordance with the US regulatory requirements known as current
Good Manufacturing Practices (cGMP). In June 1998, Phytogen
completed its US Food and Drug Administration (FDA) and
Canadian Health Protection Branch (HPB) pre-approval
inspections of its facility and processes with respect to the
Companys production of paclitaxel active pharmaceutical
ingredient ('API'), Phytogens first commercial product. Both
agencies confirmed that the Company is in compliance with cGMP
guidelines and both approved Phytogen as a producer of API.
Such approval enables the Company to sell its paclitaxel API
worldwide.
In April 2000, the Company received a Notice of Allowance from
the US Patent and Trademark Office regarding the acceptance of
its patent application, covering 61 separate claims on certain
aspects of its paclitaxel production processes and product
composition. The patent was issued in October,2000. A PCT has
been filed for European patent protection.
A PCT patent for the Preparation of Etoposide was issued in
January, 2001.
The company has a mutually exclusive license and supply
agreement with Mylan Pharmaceuticals Inc. for generic
paclitaxel product in the USA, Canada, and Mexico.
Phytogen is presently in seeking pharmaceutical strategic
partners for introduction of paclitaxel products in other
strategic markets.
Phytogen is also actively involved in sourcing other new
drugs for development, for both the anti-cancer and anti-
viral markets.
Company Details
Year Established:
1990
Total Sales ($CDN):
$5,000,000 - $10,000,000
Number of Employees:
30
Company Information
Fausto Taddei
Title:
Vice President
Area of Responsibility:
Finance/Accounting
Telephone:
(604) 525-5052
Fax:
(604) 525-5059
Email:
Click Here
Diane Wierzbicki
Title:
Vice President
Area of Responsibility:
Management Executive
Telephone:
(604) 525-5052
Fax:
(604) 525-5059
Email:
Click Here
Hy Foo
Title:
President
Area of Responsibility:
Management Executive
Telephone:
(604) 525-5052
Fax:
(604) 525-5059
Samuel Foo
Title:
Vice President
Area of Responsibility:
Research/Development/Engineering
Telephone:
(604) 525-5052
Fax:
(604) 525-5059
Products
Paclitaxel
Etoposide
Etoposide
Services
Biotechnology